Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ocular tear film and corneal surface represent a critical physiological system responsible for maintaining the health, protection, and optical quality of the eye. The tear film is a dynamic, multi-layered structure composed of lipids, an aqueous component, and mucins that work in concert to lubricate the ocular surface and provide a smooth refractive interface for vision (StatPearls, 2023). The corneal surface, specifically the epithelium, serves as a physical barrier and interacts with the tear film to maintain homeostasis (NIH, 2023). Pathological disruption of this system, often termed dry eye disease or keratoconjunctivitis sicca, involves a cycle of tear film instability, hyperosmolarity, and ocular surface inflammation (TFOS DEWS II, 2017). Therapeutic strategies targeting this system include the use of lubricants to supplement tear volume, lipid-based emulsions to prevent evaporation, and anti-inflammatory agents like cyclosporine or lifitegrast to address the underlying immune response (PubMed, 2021).
Lubrication, Immunomodulation, Lipid layer stabilization, Mucin secretion stimulation
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular tear film and corneal surface.